A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.
Related Posts
Red states hopeful for a 2nd Trump term prepare to curtail Medicaid
The Trump administration authorized 13 states’ work requirements, which tied Medicaid to employment, though only Arkansas’ got off the ground. More than 18,000 people were […]
‘Our prayer is that it doesn't even reach the ballot’: Inside Arizona’s abortion battle
Opponents of the reproductive rights referendum are waging a campaign to discourage voters from signing petitions.
‘We are flying blind’: RFK Jr.’s cuts halt data collection on abortion, cancer, HIV and more
Fired workers and outside experts say the cuts leave the nation more vulnerable to health threats.